Management to host conference call and webcast Thursday, November 20, 2025, at 8:30 AM ET

Company advances commercialization and is on track to meet year-end system deployment target

PETAH TIKVA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2025, and provided a business update.

Recent Highlights:

• Generated $3.4 million in revenue in the third quarter of 2025, compared to $3.0 million in the third quarter of 2024.
  
• Acquired 100% of the stock of Vaso Healthcare IT, a provider of healthcare information technologies solutions, for cash and future operational based earnouts.
• Secured new commercial collaborations to accelerate commercialization of the Nanox.ARC and AI Solutions globally.
• Advanced clinical work supporting the use of Nanox solutions and adding Cedars-Sinai in Los Angeles and Olympe Imagerie in Paris as clinical trial sites.
• Made inroads into the European market, signing ARC distribution partnerships with EXRAY, a Czech imaging equipment distributor, and Althea France SARL, one of Europe’s largest independent providers of medical technology services.
  
  

“We made a significant progress across our three strategic growth pillars in the third quarter. These pillars focus on advancing Nanox technologies and market expansion, continuing to build out our AI infrastructure, and doing all of this with improved operational efficiency,” said Erez Meltzer, Nanox Chief Executive Officer and Acting Chairman of the Board. “During the quarter, we entered into multiple collaborations around the world to advance commercialization of both the Nanox.ARC and AI solutions, capped by the acquisition of Vaso Healthcare IT which aims to enlarge our growing AI solutions business. Our organization is focused on execution and is well-positioned to build on our momentum in the coming years.”

Financial results for three months ended September 30, 2025

For the three months ended September 30, 2025 (the “Reported Period”), the Company reported a net loss of $13.7 million, compared to a net loss of $13.6 million for the three months ended September 30, 2024 (the “Comparable Period”), representing an increase of $0.1 million.

The Company reported revenue of $3.4 million in the Reported Period, compared to $3.0 million in the Comparable Period. During the Reported Period, the Company generated revenue through teleradiology services, the sale and deployment of its imaging systems and its AI solutions.

The Company’s gross loss during the Reported Period totaled $2.9 million (gross loss margin of (84%)) on a GAAP basis, compared to $2.8 million (gross loss margin of (93%)) in the Comparable Period. Non-GAAP gross loss for the Reported Period was $0.3 million (gross loss margin of approximately (8%)), compared to gross loss of $0.2 million (gross loss margin of approximately (6%)) in the Comparable Period.

The Company’s revenue from teleradiology services for the Reported Period was $3.1 million, compared to revenue of $2.6 million in the Comparable Period. The Company’s GAAP gross profit from teleradiology services for the Reported Period was $0.8 million (gross profit margin of approximately 25%), compared to $0.3 million (gross profit margin of approximately 13%) in the Comparable Period. Non-GAAP gross profit of the Company’s teleradiology services for the Reported Period was $1.3 million (gross profit margin of approximately 43%) compared to $0.9 million (gross profit margin of approximately 35%) in the Comparable Period. The increases in the Company’s revenue and gross profit margins from teleradiology services were mainly attributable to customer retention, increased rates and increased volume of the Company’s teleradiology reading services during the weekdays and weekends.

During the Reported Period, the Company generated revenue through the sales and deployment of its imaging systems and OEM services which amounted to $175 thousand for the Reported Period, with a gross loss of $1.7 million on a GAAP and non-GAAP basis, compared to a revenue of $29 thousand with a gross loss of $1.5 million on a GAAP basis and Non-GAAP basis in the Comparable Period.

The Company’s revenue from its AI solutions for the Reported Period was $142 thousand with a gross loss of $1.9 million on a GAAP basis, compared to a revenue of $434 thousand with a gross loss of $1.6 million in the Comparable Period. Non-GAAP gross profit of the Company’s AI solutions for the Reported Period was $75 thousand, compared to Non-GAAP gross profit of $370 thousand in the Comparable Period.

Research and development expenses, net of grants received, for the Reported Period were $4.6 million compared to $4.7 million in the Comparable Periods, reflecting a decrease of $0.1 million. The decrease was mainly due to a decrease of $0.4 million in share-based compensation and $0.5 million in expenses related to our development activities which were mitigated by an increase of $0.5 million in salaries and wages and a decrease of $0.3 million in grants received.

Sales and marketing expenses for the Reported Period were $1.5 million compared to $0.9 million in the Comparable Period which represents an increase of $0.6 million, mainly due to an increase of $0.5 million in salaries and wages and $0.1 million in marketing activities with connection to the commercialization in the U.S. market which were mitigated by a decrease of $0.1 million in share-based compensation.

General and administrative expenses for the Reported Period were $5.3 million, compared to $5.7 million in the Comparable Period. The decrease of $0.4 million was mainly due to a decrease of $0.6 million in share-based compensation, decrease of $0.2 million in the Company’s legal expenses and a decrease of $0.2 million in D&O insurance expenses which was mitigated by an increase of $0.3 million in salaries and wages and an increase of $0.2 million in recruiting fees with connection to the commercialization in the U.S. market and employees recruitment.

Non-GAAP net loss attributable to ordinary shares for the Reported Period was $9.9 million, compared to $8.7 million in the Comparable Period. The increase of $1.2 million was mainly due to an increase of $0.1 million in the Non-GAAP gross loss and an increase of $1.1 million in the Non-GAAP operating expenses.

Non-GAAP gross loss for the Reported Period was $0.3 million, compared to a non-GAAP gross loss of $0.2 million in the Comparable Period. Non-GAAP research and development expenses, net of grants received for the Reported Period, were $4.3 million, compared to $4.0 million in the Comparable Period. Non-GAAP sales and marketing expenses for the Reported Period were $1.3 million, compared to $0.6 million in the Comparable Period. Non-GAAP general and administrative expenses for the Reported Period were $4.6 million, compared to $4.5 million in the Comparable Period.

The difference between the GAAP and non-GAAP financial measures above is mainly attributable to amortization of intangible assets, share-based compensation, expenses related to an offering and legal fees in connection with the class-action litigation. A reconciliation between GAAP and non-GAAP financial measures for the three and nine months periods ended September 30, 2025, and 2024 is provided in the financial results that are part of this press release.

Limited Guidance

Based on current market conditions and assuming that macroeconomic trends, including tariff policy, inflation, interest rate levels and supply chain costs do not materially impede activity in the medical technology industry generally, or for the Company specifically, the Company anticipates that the number of clinical, demo, and commercial units in various stages of deployment will grow to over 100 units by the end of 2025, on a worldwide basis.

2026 Full-Year Guidance

The guidance that follows supersedes all prior financial guidance or outlook statements made by the Company, constitutes forward-looking information within the meaning of applicable securities laws, and is based on a number of assumptions and subject to a number of risks. Actual results could vary materially as a result of numerous factors, including certain known and unknown uncertainties and risks factors, many of which are beyond the Company’s control. Please see “Forward-Looking Statements” below for more information.

• For the year 2026 we expect revenues to reach $35 million.
    

Liquidity and Capital Resources

As of September 30, 2025, the Company had total cash, cash equivalents, short-term and long-term deposits and marketable securities of $55.5 million, compared to $83.2 million as of December 31, 2024. During the reported period the Company experienced negative cash flow from operations of $30.4 million.

Other Assets

As of September, 30, 2025 the Company had property and equipment of $46.8 million, compared to $45.4 million as of December 31, 2024.

As of September 30, 2025, the Company had intangible assets of $62.0 million compared to $70.0 million as of December 31, 2024. The decrease was attributable to the periodic amortization of intangible assets in the amount of $8.0 million. 

Shareholders’ Equity

As of September 30, 2025 the Company had approximately 65.4 million shares outstanding compared to 63.8 million shares outstanding as of December 31, 2024. During the third quarter of 2025, the Company sold approximately 1.4 million ordinary shares, which generated net proceeds of approximately $5.7 million, pursuant to the Company’s previously announced Controlled Equity Offering^SM Sales Agreement, dated as of June 7, 2024 with Cantor Fitzgerald & Co. and Mizuho Securities USA LLC (collectively, the “Agents”) relating to the issuance and sale from time to time of the Company’s ordinary shares, an aggregate offering price of up to $100 million from time to time through the Agents pursuant to the sales agreement.

Conference Call and Webcast Details

Thursday, November 20, 2025 @ 8:30am ET

Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Nanox website under Events & Presentations. Alternatively, individuals can register online to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event.

About Nanox:

Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source.

Nanox’s vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI to enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment and maintaining a clinically driven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source digital tomosynthesis system that is cost-effective and user-friendly; an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases, through Nanox’s subsidiary, Nanox.AI Ltd; Nanox.CLOUD – a cloud-based software platform that manages and stores data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. For more information, please visit www.nanox.vision

Forward-Looking Statements

This press release may contain forward-looking statements and forward-looking information (collectively, the “forward-looking statements”), that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to: guidance with respect to the number of units that the Company will have deployed by the end of the 2025 year the Company’s financial outlook, including expected revenue for the next fiscal year; the ability to successfully integrate VHC IT following the acquisition as well as to improve deployment speed pace and implementation quality; the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC; and the ability of the Company to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of its recent acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks relating to macroeconomic factors, including tariff policy, inflation, interest rate levels and supply chain costs; and (xi) potential litigation associated with our transactions; (xii) the Company’s ability to maintain expected growth and manage expenses.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. The forward-looking statements are provided to give additional information about management’s expectations and beliefs and may not be appropriate for other purposes. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.

Non-GAAP Financial Measures

This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), including non-GAAP net loss attributable to ordinary shares, non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses and non-GAAP basic and diluted loss per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. These non-GAAP measures are adjusted for (as applicable) amortization of intangible assets, share-based compensation expenses, expenses relating to an offering and legal fees in connection with class-action litigation. The Company’s management and board of directors utilize these non-GAAP financial measures to evaluate the Company’s performance. The Company provides these non-GAAP measures of the Company’s performance to investors because management believes that these non-GAAP financial measures, when viewed with the Company’s results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, these non-GAAP measures are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, these non-GAAP measures should not be considered measures of the Company’s liquidity. A reconciliation of certain GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

Investors
Mike Cavanaugh
ICR Healthcare
Mike.cavanaugh@icrhealthcare.com

Media
ICR Healthcare
NanoxPR@icrinc.com

Use of Non-GAAP Financial Measures

The unaudited condensed consolidated financial information is prepared in conformity with GAAP. The Company uses information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net loss attributable to ordinary shares, non-GAAP cost of revenue, non-GAAP gross profit (loss), non-GAAP gross profit (loss) margin, non-GAAP research and development expenses, net, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP other expenses (income) and non-GAAP basic and diluted loss per share. These non-GAAP measures are adjusted for (as applicable) amortization of intangible assets, share-based compensation expenses, expenses related to an offering and legal fees expenses in connection with class-action litigation. The Company believes that separate analysis and exclusion of the one-off or non-cash impact of the above reconciling items (as applicable) adds clarity to the constituent parts of its performance. The Company reviews these non-GAAP financial measures together with GAAP financial measures to obtain a better understanding of its operating performance. It uses the non-GAAP financial measures for planning, forecasting, and measuring results against the forecast. The Company believes that the non-GAAP financial measures are useful supplemental information for investors and analysts to assess its operating performance. However, these non-GAAP measures are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance.

Reconciliation of GAAP net loss attributable to ordinary shares to Non-GAAP net loss attributable to ordinary shares and Non-GAAP basic and diluted loss per share (U.S. dollars in thousands)

Reconciliation of GAAP cost of revenue to Non-GAAP cost of revenue (U.S. dollars in thousands)

Reconciliation of GAAP gross loss to Non-GAAP gross profit (U.S. dollars in thousands)

Reconciliation of GAAP gross loss margin to Non-GAAP gross profit margin (in percentage of revenue)

Reconciliation of GAAP research and development, expenses to Non-GAAP research and development expenses, net (U.S. dollars in thousands)

Reconciliation of GAAP sales and marketing expenses to Non-GAAP sales and marketing expenses (U.S. dollars in thousands)

Reconciliation of GAAP general and administrative expenses to Non-GAAP general and administrative expenses (U.S. dollars in thousands)